Intercept Pharmaceuticals, Inc.
http://www.interceptpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Intercept Pharmaceuticals, Inc.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
All Over For Acorda After A Torrid Few Years
The embattled US biotech has gone into Chapter 11 and linked up with 'stalking horse' bidder Merz which has offered $185m to get hold of Ampyra for multiple sclerosis and Parkinson’s therapy Inbrija.
Keeping Track: Cardio-Renal Drugs At Heart Of US FDA’s March Approval Binge
Seven novel agents approved in March include one accelerated approval, two rare pediatric disease priority review vouchers, two breakthrough therapy designations and one regenerative medicine advance therapy designation.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice